The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
Open accessAbstract
Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4+ and CD8+ T cells. LDRT elicited predominantly CD4+ cells with features of exhausted effector cytotoxic cells, with a subset expressing NKG2D and exhibiting proliferative capacity, as well as a unique subset of activated dendritic cells expressing the NKG2D ligand RAE1. We translated these findings to a phase I clinical trial administering LDRT, low-dose cyclophosphamide, and immune checkpoint blockade to patients with immune-desert tumors. In responsive patients, the combinatorial treatment triggered T-cell infiltration, predominantly of CD4+ cells with Th1 signatures. Our data support the rational combination of LDRT with immunotherapy for effectively treating low T cell–infiltrated tumors. Significance: Low-dose radiation reprogrammed the tumor microenvironment of tumors with scarce immune infiltration and together with immunotherapy induced simultaneous mobilization of innate and adaptive immunity, predominantly CD4+ effector T cells, to achieve tumor control dependent on NKG2D. The combination induced important responses in patients with metastatic immune-cold tumors. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Patients with socalled cold or immune-desert tumors are, however, less likely to respond to ICB (1, 2).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris
The Tabula Muris Consortium, coordination, O., coordination, L., processing, O. C. A., sequencing, L. P. A., analysis, C. D., annotation, C. T., Writing group, Supplemental text writing group, & Principal investigators (2018) · Nature · doi:10.1038/s41586-018-0590-4 · Cited by 2,842
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“Moreover, hypo-fractionated radiotherapy may trigger systemic antitumor immunity enabling control of distal metastases, the so-called abscopal effect (3), and synergizes with ICB in preclinical studies (5, 10–13) and in patients (4, 14).”
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679
Self-citationCD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646 · cited 1×
“In this context, Tox ensures stable commitment to the exhausted state (33, 76, 77).”
BackgroundTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Zhang, L., Li, Z., Skrzypczynska, K. M., Fang, Q., Zhang, W., O’Brien, S. A., He, Y., Wang, L., Zhang, Q., Kim, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.048 · Cited by 1,526
Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H. D., Krishnan, I., Maroni, G., Meyerovitz, C. V., Kerwin, C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.009 · Cited by 1,475
Self-citationCD8+ T cell states in human cancer: insights from single-cell analysis
van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,472
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
TOX is a critical regulator of tumour-specific T cell differentiation
Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
A smart local moving algorithm for large-scale modularity-based community detection
Waltman, L., & van Eck, N. J. (2013) · The European Physical Journal B · doi:10.1140/epjb/e2013-40829-0 · Cited by 1,088 · cited 1×
“Then, the shared nearest-neighbor (SNN) clustering method (111) implemented in Seurat 3 as the FindClusters function was applied, with parameter resolution = 0.”
MethodUtzschneider, D. T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D. P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.021 · Cited by 1,085
Beltra, J.-C., Manne, S., Abdel-Hakeem, M. S., Kurachi, M., Giles, J. R., Chen, Z., Casella, V., Ngiow, S. F., Khan, O., Huang, Y. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.014 · Cited by 1,082
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Self-citationDemaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 1×
“5); (iii) the release of danger signals and the upregulation of cytokines and chemokines (6); and (iv) normalization of the tumor vasculature (7).”
BackgroundA conserved dendritic-cell regulatory program limits antitumour immunity
Maier, B., Leader, A. M., Chen, S. T., Tung, N., Chang, C., LeBerichel, J., Chudnovskiy, A., Maskey, S., Walker, L., Finnigan, J. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2134-y · Cited by 941
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928 · cited 2×
“Moreover, hypofractionated radiotherapy may trigger systemic antitumor immunity enabling control of distal metastases, the so-called abscopal effect (3), and synergizes with ICB in preclinical studies (5, 10–13) and in patients (4, 14).”
BackgroundLutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 899
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875 · cited 1×
“radiotherapy (LD-WART) in ovarian cancer, we chose the orthotopic intraperitoneal (i.p.) murine ID8 model (22), characterized as being propense to losing intraepithelial T cells with progression in vivo (23).”
Self-citationSPICE: Exploration and analysis of post‐cytometric complex multivariate datasets
Roederer, M., Nozzi, J. L., & Nason, M. C. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21015 · Cited by 831
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Sinha, P., Clements, V. K., Fulton, A. M., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4174 · Cited by 755
Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01638 · Cited by 736 · cited 1×
“This is quite remarkable in this patient population (92-94), especially considering that we treated only patients with”
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.017 · Cited by 734
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T. O., Babb, J. S., Schneider, R. J., Formenti, S. C., Dustin, M. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.3099 · Cited by 711
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia, J., Rozenblatt-Rosen, O., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.014 · Cited by 636
Crozat, K., Guiton, R., Contreras, V., Feuillet, V., Dutertre, C.-A., Ventre, E., Vu Manh, T.-P., Baranek, T., Storset, A. K., Marvel, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100223 · Cited by 629
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
scRepertoire: An R-based toolkit for single-cell immune receptor analysis
Borcherding, N., & Bormann, N. L. (2020) · F1000Research · doi:10.12688/f1000research.22139.1 · Cited by 603
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · cited 1×
“) murine ID8 model (22), characterized as being propense to losing intraepithelial T cells with progression in vivo (23).”
BackgroundLow and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 576
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Baratelli, F., Lin, Y., Zhu, L., Yang, S.-C., Heuzé-Vourc’h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., & Dubinett, S. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1483 · Cited by 573
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Interpretation of T cell states from single-cell transcriptomics data using reference atlases
Andreatta, M., Corria-Osorio, J., Müller, S., Cubas, R., Coukos, G., & Carmona, S. J. (2021) · Nature Communications · doi:10.1038/s41467-021-23324-4 · Cited by 541
Self-citationMoynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J. M., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 524
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Self-citationGroh, V., Brühl, A., El-Gabalawy, H., Nelson, J. L., & Spies, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1632807100 · Cited by 506
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J. M., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 496
Sánchez-Paulete, A. R., Cueto, F. J., Martínez-López, M., Labiano, S., Morales-Kastresana, A., Rodríguez-Ruiz, M. E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M. A., Quetglas, J. I., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0510 · Cited by 484
Precursor exhausted T cells: key to successful immunotherapy?
Kallies, A., Zehn, D., & Utzschneider, D. T. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0223-7 · Cited by 465
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E.-K. M., Muranski, P., Restifo, N. P., & Antony, P. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 457
Dorner, B. G., Dorner, M. B., Zhou, X., Opitz, C., Mora, A., Güttler, S., Hutloff, A., Mages, H. W., Ranke, K., Schaefer, M., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.027 · Cited by 456
Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A. M., Hsia, J. K., Vivier, E., & Raulet, D. H. (2002) · Nature Immunology · doi:10.1038/ni858 · Cited by 452
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Grajales-Reyes, G. E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., KC, W., Kretzer, N. M., Briseño, C. G., Durai, V., Bagadia, P., et al. (2015) · Nature Immunology · doi:10.1038/ni.3197 · Cited by 399
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Paczulla, A. M., Rothfelder, K., Raffel, S., Konantz, M., Steinbacher, J., Wang, H., Tandler, C., Mbarga, M., Schaefer, T., Falcone, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1410-1 · Cited by 391
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821218116 · Cited by 359 · cited 3×
“To attenuate macrophage suppression, we used aspirin, which prevents prostaglandin E 2 (PGE 2 )-mediated inhibition of DCs, attenuates Tregs and myeloid-derived suppressor cells (101, 102), and reduces endothelial FasL-mediated killing of homing effector T cells (51).”
Fairfax, B. P., Taylor, C. A., Watson, R. A., Nassiri, I., Danielli, S., Fang, H., Mahé, E. A., Cooper, R., Woodcock, V., Traill, Z., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0734-6 · Cited by 341
Brown, D. M., Lee, S., Garcia-Hernandez, M. D. L. L., & Swain, S. L. (2012) · Journal of Virology · doi:10.1128/jvi.07172-11 · Cited by 248
Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx235 · Cited by 244
Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Le, D. T., & Jaffee, E. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3912 · Cited by 240
Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D. F., Ghorani, E., Akarca, A. U., Marzolini, M. A. V., Solomon, I., Vargas, F. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.007 · Cited by 228
Barsoumian, H. B., Ramapriyan, R., Younes, A. I., Caetano, M. S., Menon, H., Comeaux, N. I., Cushman, T. R., Schoenhals, J. E., Cadena, A. P., Reilly, T. P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000537 · Cited by 225
On determining sample size in experiments involving laboratory animals
Festing, M. F. (2018) · Laboratory Animals · doi:10.1177/0023677217738268 · Cited by 213
Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
Zhong, W., Myers, J. S., Wang, F., Wang, K., Lucas, J., Rosfjord, E., Lucas, J., Hooper, A. T., Yang, S., Lemon, L. A., et al. (2020) · BMC Genomics · doi:10.1186/s12864-019-6344-3 · Cited by 184
Cutting Edge: NKG2D Is a Costimulatory Receptor for Human Naive CD8+ T Cells
Maasho, K., Opoku-Anane, J., Marusina, A. I., Coligan, J. E., & Borrego, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4480 · Cited by 180
Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease
Antonczyk, A., Krist, B., Sajek, M., Sekrecka, A., Piaszyk-Borychowska, A., Plens-Gałąska, M., Wesoły, J., & Bluyssen, H. A. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01176 · Cited by 177
Scurr, M., Pembroke, T., Bloom, A., Roberts, D., Thomson, A., Smart, K., Bridgeman, H., Adams, R., Brewster, A., Jones, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0895 · Cited by 171
Fas ligand–mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity
Groh, V., Smythe, K., Dai, Z., & Spies, T. (2006) · Nature Immunology · doi:10.1038/ni1350 · Cited by 167
Lanitis, E., Rota, G., Kosti, P., Ronet, C., Spill, A., Seijo, B., Romero, P., Dangaj, D., Coukos, G., & Irving, M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20192203 · Cited by 163
Self-citationRational combinations of immunotherapy with radiotherapy in ovarian cancer
Herrera, F. G., Irving, M. B., Kandalaft, L. E., & Coukos, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30401-2 · Cited by 162
Self-citationHirschhorn-Cymerman, D., Budhu, S., Kitano, S., Liu, C., Zhao, F., Zhong, H., Lesokhin, A. M., Avogadri-Connors, F., Yuan, J., Li, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120532 · Cited by 159
Qui, H. Z., Hagymasi, A. T., Bandyopadhyay, S., St. Rose, M.-C., Ramanarasimhaiah, R., Ménoret, A., Mittler, R. S., Gordon, S. M., Reiner, S. L., Vella, A. T., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101244 · Cited by 158
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149 · cited 1×
“The NKG2D pathway likely plays an important role in tumor immune elimination, since tumors develop numerous mechanisms to evade NKG2D (82-85), and neutralization of soluble NKG2D ligands enhances response to ICB (86).”
BackgroundGeoMx™ RNA Assay: High Multiplex, Digital, Spatial Analysis of RNA in FFPE Tissue
Zollinger, D. R., Lingle, S. E., Sorg, K., Beechem, J., & Merritt, C. R. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0623-0_21 · Cited by 145
Kitano, S., Tsuji, T., Liu, C., Hirschhorn-Cymerman, D., Kyi, C., Mu, Z., Allison, J. P., Gnjatic, S., Yuan, J. D., & Wolchok, J. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0068 · Cited by 144
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 135
Self-citationMa, H. S., Poudel, B., Torres, E. T. R., Sidhom, J.-W., Robinson, T. M., Christmas, B. J., Scott, B., Cruz, K. A., Woolman, S., Wall, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0061 · Cited by 133
Markiewicz, M. A., Carayannopoulos, L. N., Naidenko, O. V., Matsui, K., Burack, R., Wise, E. L., Fremont, D. H., Allen, P. M., Yokoyama, W. M., Colonna, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.2825 · Cited by 126
Heylmann, D., Bauer, M., Becker, H., Gool, S. V., Bacher, N., Steinbrink, K., & Kaina, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083384 · Cited by 119
Transcriptomes of the B and T Lineages Compared by Multiplatform Microarray Profiling
Painter, M. W., Davis, S. P., Hardy, R. R., Mathis, D. J., Benoist, C. O., Zhou, Y., Shinton, S. A., Hardy, R. R., Asinovski, N., Davis, S. P., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002695 · Cited by 105
Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression
Peeters, L. M., Vanheusden, M., Somers, V. A., Wijmeersch, B. V., Stinissen, P., Broux, B., & Hellings, N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01160 · Cited by 99
Low‐dose radiation may be a novel approach to enhance the effectiveness of cancer therapeutics
Yang, G., Li, W., Jiang, H., Liang, X., Zhao, Y., Yu, D., Zhou, L., Wang, G., Tian, H., Han, F., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30235 · Cited by 94
The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease
Stojanovic, A., Correia, M. P., & Cerwenka, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00827 · Cited by 93
Serroukh, Y. I. M., Gu‐Trantien, C., Kashani, B. H., Defrance, M., Manh, T. V., Azouz, A., Detavernier, A., Hoyois, A., Das, J., Bizet, M., et al. (2018) · eLife · doi:10.7554/elife.30496 · Cited by 87
The Transcription Factor Hobit Identifies Human Cytotoxic CD4+ T Cells
Oja, A. E., Braga, F. A. V., Remmerswaal, E. B. M., Kragten, N. A. M., Hertoghs, K. M. L., Zuo, J., Moss, P. A. H., van Lier, R. A. W., van Gisbergen, K. P. J. M., & Hombrink, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00325 · Cited by 73
Papadopoulos, K. P., Johnson, M. L., Lockhart, A. C., Moore, K., Falchook, G. S., Formenti, S. C., Naing, A., Carvajal, R. D., Rosen, L. S., Weiss, G. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2609 · Cited by 66
Eliçin, O., Callaway, S., Prior, J. O., Bourhis, J., Özşahin, M., & Herrera, F. G. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.08.017 · Cited by 56
Self-citationKunos, C. A., Sill, M. W., Buekers, T., Walker, J. L., Schilder, J. M., Yamada, S. D., Waggoner, S. E., Mohiuddin, M., & Fracasso, P. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.10.018 · Cited by 51
Zhang, J., Larrocha, P. S.-L., Zhang, B., Wainwright, D. A., Dhar, P., & Wu, J. D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0693-y · Cited by 38
García‐Chagollán, M., Jave‐Suárez, L. F., Haramati, J., Bueno‐Topete, M. R., Aguilar‐Lemarroy, A., Estrada‐Chávez, C., Bastidas‐Ramírez, B. E., Pereira-Suárez, A. L., & del Toro‐Arreola, S. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0190-7 · Cited by 15
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Rahim, M. K., Okholm, T. L. H., Jones, K. B., McCarthy, E. E., Liu, C. C., Yee, J. L., Tamaki, S. J., Marquez, D. M., Tenvooren, I., Wai, K., et al. (2023) · Cell · doi:10.1016/j.cell.2023.02.021 · Cited by 455
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 368
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Metadata
- Authors
- Herrera, F. G., Ronet, C., Ochoa de Olza, M., Barras, D., Crespo, I., Andreatta, M., Corria-Osorio, J., Spill, A., Benedetti, F., Genolet, R., Orcurto, A., Imbimbo, M., Ghisoni, E., Navarro Rodrigo, B., Berthold, D. R., Sarivalasis, A., Zaman, K., Duran, R., Dromain, C., Prior, J., Schaefer, N., Bourhis, J., Dimopoulou, G., Tsourti, Z., Messemaker, M., Smith, T., Warren, S. E., Foukas, P., Rusakiewicz, S., Pittet, M. J., Zimmermann, S., Sempoux, C., Dafni, U., Harari, A., Kandalaft, L. E., Carmona, S. J., Dangaj Laniti, D., Irving, M., & Coukos, G.
- Venue
- Cancer Discovery
- Published
- 2021-09-03
- Volume
- 12
- Issue
- 1
- Pages
- 108-133
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3197979465
- Cited by
- 451
- References
- 110
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.